Q3 2017 EPS Estimates for Exact Sciences Corporation Boosted by Analyst (EXAS)
Exact Sciences Corporation (NASDAQ:EXAS) – Investment analysts at Craig Hallum lifted their Q3 2017 EPS estimates for shares of Exact Sciences Corporation in a report released on Thursday. Craig Hallum analyst B. Bonello now forecasts that the medical research company will post earnings per share of ($0.35) for the quarter, up from their previous estimate of ($0.38). Craig Hallum also issued estimates for Exact Sciences Corporation’s Q4 2017 earnings at ($0.36) EPS, FY2017 earnings at ($1.41) EPS, Q1 2018 earnings at ($0.33) EPS, Q2 2018 earnings at ($0.33) EPS and FY2018 earnings at ($1.28) EPS.
EXAS has been the subject of several other research reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $25.00 price objective on shares of Exact Sciences Corporation in a research report on Wednesday, April 26th. Cowen and Company upped their price objective on shares of Exact Sciences Corporation from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday, May 15th. Leerink Swann set a $38.00 price objective on shares of Exact Sciences Corporation and gave the stock a “buy” rating in a research report on Friday, April 28th. Vetr cut shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $36.37 target price for the company. in a report on Thursday, July 6th. Finally, Roth Capital reissued a “buy” rating and issued a $40.00 target price (up previously from $33.00) on shares of Exact Sciences Corporation in a report on Thursday, June 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company’s stock. Exact Sciences Corporation has a consensus rating of “Buy” and a consensus price target of $33.75.
Exact Sciences Corporation (NASDAQ:EXAS) opened at 37.93 on Monday. The company’s market capitalization is $4.22 billion. The company’s 50-day moving average is $33.86 and its 200 day moving average is $24.14. Exact Sciences Corporation has a one year low of $11.94 and a one year high of $38.92.
Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings results on Thursday, April 27th. The medical research company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.09. Exact Sciences Corporation had a negative net margin of 116.39% and a negative return on equity of 49.24%. The firm had revenue of $48.36 million during the quarter, compared to the consensus estimate of $37.38 million. During the same period last year, the firm posted ($0.49) EPS. The firm’s quarterly revenue was up 225.9% on a year-over-year basis.
Hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. purchased a new stake in Exact Sciences Corporation during the fourth quarter worth $192,000. Botty Investors LLC purchased a new stake in Exact Sciences Corporation during the first quarter worth $200,000. Eqis Capital Management Inc. purchased a new stake in Exact Sciences Corporation during the first quarter worth $201,000. Teacher Retirement System of Texas purchased a new stake in Exact Sciences Corporation during the first quarter worth $203,000. Finally, Ameritas Investment Partners Inc. increased its stake in Exact Sciences Corporation by 455.0% in the first quarter. Ameritas Investment Partners Inc. now owns 9,129 shares of the medical research company’s stock worth $216,000 after buying an additional 7,484 shares in the last quarter. 84.96% of the stock is owned by institutional investors and hedge funds.
In other Exact Sciences Corporation news, SVP D Scott Coward sold 1,987 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $35.21, for a total transaction of $69,962.27. Following the completion of the sale, the senior vice president now owns 57,603 shares of the company’s stock, valued at approximately $2,028,201.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.00% of the company’s stock.
Exact Sciences Corporation Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.